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Abstract-~-To evaluate the differential charges for treatmg end-stage renal disease (ESRD) 
associated with diabetes mellitus. Medicare billmg data are analyzed. The charges of 244 patients 
in the Michigan Kidney Registry Identified as havmg (ESRD) from diabetes are compared with 
charges of 902 nondiabetic patients. Average annual charges for ESRD treatment for diabetics are 
S29,671 (k 27.662) which are $4695 (+ 1344) higher than charges for nondiabetics. The majorit) 
of the difTerence (84.3%) is attributable to higher inpatient hospital charges. Most of the remainder 
(14.5%) is attributable to higher physician and medlcal supply charges. Charges for treatment of 
diabetics are higher on all modalities of treatment, but differences are not significant among 
modalities. 
Charges Diabetes End-stage renal disease 
INTRODUCTION 
The treatment of end-stage renal disease 
(ESRD) in the United States consumes over 
$2.5 billion every year [I]. Currently, diabetes 
mellitus represents the primary diagnosis for 
nearly one quarter of all patients on ESRD 
treatment [2]. In recent years the number of 
diabetics being accepted onto ESRD treatment 
programs has been increasing both in the U.S. 
and throughout Europe [3,4]. The European 
Dialysis and Transplant Registry reported an 
increase in the proportion of diabetics accepted 
from less than 0.5% in 1972 to 7.3% by 1981 [4]. 
This registry also reported diabetes to be the 
only primary cause of ESRD which is increasing 
in all industrialized countries [5]. Knowles has 
estimated that 50% of the patients with insulin 
dependent diabetes mellitus will progress to 
ESRD [6]. Clearly ESRD in diabetics is a major 
health concern which generates substantial med- 
ical costs. 
Few previous studies have examined the cost 
of ESRD treatment for diabetic patients, and 
there are no studies which have examined the 
cost of ESRD treatment for diabetic patients by 
modality adjusting for patient characteristics. 
Beltzer el al. found that hospital costs for the 
year after a transplant were $1507 and $2600 
higher for diabetics than nondiabetics receiving 
living-related and cadaveric transplants. re- 
spectively [7]. Costs associated with living- 
related transplants were found to be lower than 
costs associated with cadaver transplants for 
both diabetics and nondiabetics. Evans er al. 
adjusted for case-mix factors and found annual 
outpatient provider reimbursement to be $1646 
lower for diabetics than for nondiabetics, but 
physician reimbursement, inpatient and total 
reimbursement were $2868, $5310 and $6532 
higher, respectively [8]. Some reimbursement 
comparisons by modality were made in general 
by Evans et al., but not specifically for diabetics. 
In this study we provide specific information 
on Medicare allowable charges for treatment of 
ESRD in diabetics and compare them to 
charges for treatment in nondiabetics, adjusting 
for selection and patient characteristics. We also 
examine these charges by treatment modality in 
an attempt to identify those treatment modali- 
ties which might be less expensive. If any modal- 
ities were found to be less expensive there would 
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be potential for savings in the large expenditures 
for ESRD treatment in diabetics. 
MATERIALS AND METHODS 
Data for this study come from the Health 
Care Financing Administration (HCFA) 
through the Urban Institute. The sample was 
derived by requesting data on all ESRD patients 
in Michigan from 1982-1984 with onset of 
ESRD from 1981-1983, as identified by the 
Michigan Kidney Registry (MKR). The deci- 
sion rule for admission to the sample was onset 
of ESRD. The aim, therefore, was to observe 
the entire population. An observation is defined 
as having complete information on a patient for 
a particular year, for however long the patient 
was alive and had ESRD during that year. 
There are between one and three obervations for 
each patient, depending on time of death, year 
of onset of ESRD, and data availability. How- 
ever, there are no observations on some patients 
because of death in 198 1. Using the average rate 
of death for patients dying in 1982 and 1983 as 
their first year of ESRD, ony approximately 18 
too few patients in sample of 2292 (0.8%) were 
included in the study. Therefore, e sample is 
only slightly biased in overreprese 
f 
’ ing patients 
surviving their first year of ESRD., A matching 
of HCFA and MKR data resulted/ in a sample 
of 487 annual (calendar year) observations on 
243 diabetic patients and 1805 annual obser- 
vations on 903 nondiabetic patients. This repre- 
sents a match rate of approximately 62% (1146 
out of 1832) between the complete HCFA 
records and MKR data. 
Charges 
The HCFA data include charges for medical 
services from provider billing records, and mo- 
dality and patient characteristics information 
from the Patient Management-Medical Infor- 
mation System (PMMIS). Charges are defined 
as Medicare allowable charges. These charges 
are the sum of the reimbursement amounts paid 
by Medicare to providers and the copayments 
and deductibles paid directly by the patient. 
Medicare reimbursement amounts account for 
slightly under 80% of total charges. This 
measure of charges does not include payments 
for services not covered by Medicare, such as 
private duty nurses and transportation to a 
dialysis center or outpatient facility, It is now 
known how charges which are not covered by 
Medicare vary by modality or are different for 
diabetic and nondiabetic patients. The lack of 
this information is a potential limitation of this 
and any other study which uses only Medicare 
billing data as a measure of charges. 
Medicare reimbursements for dialysis treat- 
ments and physician services are paid under 
Part B and are based on predetermined fixed 
rates which are identical for home and center 
dialysis. Hospital reimbursement is paid on the 
basis of diagnosis-related groups (DRGs) which 
also involve predetermined fixed rates. The ex- 
tent to which diabetics incur larger levels of 
charges and reimbursements is, therefore, more 
closely associated with a greater number of 
visits to health care providers than to larger 
payment amounts per visit. Medicare allowable 
changes do not reflect any increased intensity of 
treatment due to diabetes, and may, therefore, 
lead to a conservative estimate of the additional 
cost of treating ESRD in diabetics. 
Modality 
The modalities of treatment were defined 
using the scheme of Smith and Wheeler [9]. This 
definition of modality is based on annual aggre- 
gation of quarterly records of actual treatments 
received and designed specifically for this type 
of analysis. Defining modality in this way per- 
mits a close correspondence between modality 
and charges. Alternative definitions of modality, 
such as initial treatment or primary treatment, 
may be useful for survival or other analyses, 
but not for studies which attempt to match 
charges and treatment. This definition of modal- 
ity includes the following treatments: the use 
of single, well-defined dialysis treatments [in- 
center hemodialysis (CHD), in-center perito- 
neal dialysis (PERI), and at-home continuous 
ambulatory peritoneal dialysis (CAPDH)], 
combinations of dialysis treatments [continu- 
ous ambulatory peritoneal dialysis training 
(CAPDTR), and other combinations of treat- 
ments (OTHER)], and transplants from living- 
related donors (LTRAN) and cadaver donors 
(CTRAN). For some modalities, such as home 
hemodialysis and the simultaneous or sequential 
use of CHD and CAPD, there were too few 
observations on diabetics for separate analysis. 
These observations (34,7%) were excluded 
from the analysis. For each observation, again, 
a complete set of information on a patient in a 
given year, there is only one modality. For 
patients receiving multiple forms of treatment, 
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Race (% non-white) 
Sex (% female) 
Date (months) 
Time (years) 
Death (% dying) 
1982 (% observed) 
1984 (% observed) 
N-Diabetic” 
N-Non-diabetich 
Center Center Center/home Other dialysis 
hemodialysis peritoneal dialysis CAPD training Home CAPD combinations 
(CH) (PERI) (CAPDTR) (CAPDH) (OTHER) 
- 58.1 58.8 53.2 44.4 50.4 
43.7 36.8 10.3 13.3 21.4 
56.3 13.7 74.4 66.7 71.4 
9.1 8.7 8.6 8.1 10.5 
2.0 1.9 2.0 1.7 1.8 
18.9 26.3 28.2 33.3 14.3 
14.7 5.3 0.0 40.0 28.6 
38.7 26.3 64.1 13.3 21.4 
238 19 39 15 14 
868 50 147 75 86 
Transplant modality 
Living-related Diabetic Non-diabetic 
donor Cadaver donor Failed weighted weighted 
Variable (LTRAN) (CTRAN) (FTRAN) average’ average’ 
- Age (years) 37.7 38.2 35.8 51.4 51.5 
Race (X non-white) 22.2 16.7 10.4 29.8 32. I 
Sex (% female) 20.0 38.9 31.0 51.6 44.0 
Date (months) 11.2 10.5 9.7 9.8 10.1 
Time (years) 2.2 1.9 2.2 2.0 2.0 
Death (% dymg) 2.2 5.6 27.6 17.9 10.7 
1982 (X observed) 20.0 22.2 24.1 16.2 15.8 
1984 (% observed) 40.0 38.9 27.6 38.4 40.6 
N-Diabetic” 45 54 29 487 
N-Non-diabetiG 122 239 86 1805 
“The number of observations of diabetic patients upon which the average characteristics are calculated. bathe number of 
observations of non-diabetic patients. Average characteristics are not presented by modality for these patients. ‘The 
weighted averages include the observations from the additional six modalities which do not include sufficient numbers 
of observations for cost estimation 
the combinations of treatments are defined as 
distinct modalities. such as OTHER. 
The selection of a particular modality, while 
not deterministic, is not completely random. 
Patients along with their physicians select that 
modality which is believed to be the most 
appropriate form of treatment, given their con- 
dition, anticipated survival and quality-of-life. 
No formal criteria have been followed for mo- 
dality selection, as has been suggested for cancer 
patients by Simes [lo] and cadaver kidney recip- 
ients by Starzl et al. [l l] but the data suggest 
systematic selection of modalities. 
A description of the data for diabetic patients 
by modality and for the average of nondia- 
betic patients on all modalities is presented in 
Table 1. The distribution of patients by modal- 
ity is very similar for diabetics and nondiabetics 
making comparisons of average characteristics 
between the two groups reasonable. The dia- 
betic ESRD patients were, on average, nearly 
the same age as the nondiabetics. Diabetics were 
somewhat more likely to be white and female 
than nondiabetics. Diabetics also had a higher 
mortality rate during the study period. Among 
diabetics the patients were evenly divided be- 
tween the genders and nearly 30% were black. 
The type of diabetes (insulin dependent vs non- 
insulin dependent) was not known for individu- 
als in the present study. For all patients, those 
receiving transplants were more likely to be 
younger, white and male than dialysis patients, 
and successful transplant recipients were less 
likely to die during the study period. 
The other variables, number of months ob- 
served in a year (Date), time since onset of 
ESRD (Time), and a marker for the particular 
year of the observation (1982, 1984) also vary by 
modality, but their primary importance is in the 
allocation of charges. 
This sample appears to have an unusually 
large number of observations of persons using 
CAPD training. Although CAPD training typi- 
cally occurs over a period of days or weeks. 
there were many observations which listed 
CAPD training for much longer periods of time. 
This is due mostly to the unit of modality 
observation being a quarter. If any training 
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sessions are provided during a quarter then the 
defined modality for reimbursement on HCFA 
records is CAPDTR. 
Estimation 
To adjust for modality selection and differ- 
ences in patient characteristics, a two-part 
estimation technique is employed. Failure to 
account for selection would result in biased 
estimates of charges by modality [12]. In the first 
part, a self-selection probit model is estimated 
for each modality. Individual probit models for 
the selection of each modality are estimated 
using patient characteristics (age, sex, race, time 
since onset of ESRD) as determinants of selec- 
tion. A potentially important limitation of this 
study is the lack of additional patient and 
physician data which might more exactly deter- 
mine selection. It has been shown that there are 
patterns of physician treatment recommen- 
dations which are independent of the above 
listed patient characteristics [ 131. 
The probit model yields predicted values 
which are used to construct additional variables, 
so-called inverse Mill’s ratios, for each patient. 
The results from the first part, essentially, reflect 
the effects of the patient’s characteristics on 
selection of a modality. In the second part, these 
ratios are used as covariates along with the 
other patient characteristics in a multivariate 
least squares regression of the logarithm of 
annual charges. Logged charges @re used to 
avoid the problems associated with extreme 
values which are frequently encbuntered in 
health care charge data [14]. Observations of 
less than $500 for more than one quarter of a 
year and more than $200,000 are cbnsidered to 
be gross outliers and are not included in the 
sample. Inclusion of these outliers, however, 
only affects the variances of the final results and 
not the mean values. 
Standardized values of patient characteristics 
for each modality are used in the estimated 
equations to determine the charges for ESRD 
treatment by modality. The standardized value 
for length of time of observation (Date) is 12 
months and 1983 for year of observation. This 
approach is described in general by Maddala 
[ 151 and terms of specific examples by Lee and 
Trost [16]. 
This approach permits a consistent and 
asymptotically efficient method of estimated 
charges. Some limitations in the estimation pro- 
cedures, however, should be noted. First, having 
an unequal number of observations per patient 
indicates a potential lack of efficiency. This was 
not a problem in this case, as separate equations 
estimated using aggregated patient data and 
weighted least squares yielded nearly identical 
results. We also found that in time-series esti- 
mations, patients’ past charges were not sig- 
nificant predictors of current charges. These 
results might not be true in general for other 
researchers using this method and should 
always be investigated. Second, for some modal- 
ities, such as those involving training or a 
transition between treatments, for which a 
patient would usually only be in this state for a 
short period of time, annualization of charges 
may lead to deceiving results. Caution must, 
therefore, be used when comparing estimated 
charges between steady-state and transitional 
modalities of treatment. And finally, since 
charges are estimated in logs, estimated stan- 
dard deviations are also in logs. Standard 
deviations are, therefore, log-linear rather than 
linear and simple confidence intervals do not 
have the usual meaning. 
The statistical analysis was conducted using 
the Michigan Interactive Data Analysis System 
(MIDAS), a program capable of handling the 
probit and multivariate least squares regression 
analyses required by this two-part technique. 
RESULTS 
Table 2 presents estimates of a full year’s 
charges for ESRD treatment by modality for 
diabetic and nondiabetic patients holding con- 
stant the patient characteristics of diabetic 
patients. The interpretation of these values is 
that the charges in each row represent the 
estimated annualized (12 months) charges as- 
suming that the average age, sex, race, time 
since onset of ESRD and proportion dying are 
the same for diabetic and nondiabetic patients. 
The only factor explaining the difference be- 
tween the two columns is the presence of dia- 
betes vs some other disease causing ESRD. The 
differences between rows are not adjusted for 
patient characteristics. 
On average, diabetics have annual charges of 
$29,671, which are significantly higher ($4695, 
p < 0.01) than charges for nondiabetics. 
Although standard deviations do not have their 
usual meaning in the strict sense, as an approx- 
imation for reference, a confidence interval of 
f 1344 is associated with the additional charges 
for ESRD treatment of diabetics. This adjusted 
difference in charges is less than the observed 
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Table 2. Annual charges adjusted for patient characteristics 
(1983 dollars) 






















46,197 41,553 5244 
61.493 42,074 19.419 
63.670 58,672 4998 
4320 3836 484 
8325 5696 2629 
50,584 47.057 3527 
$23,470 $3993 
22,529 3957 
18.408 - 529 
22,153 6682 
28.342 12.437 
Weighted average $29.67 I S24.976 $4.695’ 
“Indicates a significant difference from 0. p i 0.01, two-tailed test. 
hIndicates a significant difference from 0, p i 0.05, two-tailed test. 
difference in charges due mostly to the higher 
death rate of diabetics. The death rate of dia- 
betics is much higher than the death rate for 
nondiabetics, and is associated with diabetes 
independently as well as with other patient 
characteristics. The higher death rate of dia- 
betics implies a larger number of “censored” 
observations (observations of persons for less 
than a full year) for diabetics than for non- 
diabetics. Therefore, adjusted charges are rela- 
tively higher for diabetics than for nondiabetics. 
However, deaths are associated with very high 
medical charges, especially for ESRD patients 
[17]. The net effect of the adjustment for death 
rates leads to relatively higher adjusted charges 
for nondiabetics than for diabetics, and hence 
the adjusted $4695 difference is less than the 
observed difference in charges. 
Of the total difference in charges between dia- 
betics and nondiabetics, the majority (84.3%) is 
explained by differences in inpatient hospital 
charges. Differences in charges by source of 
charges are presented in Table 3. Almost all of 
the remaining difference (14.5%) is explained by 
differences in charges for physician services and 
medical supplies. There is only a very small 
difference in charges for outpatient services. 
Differences in annual charges among dialysis 
modalities were not significant, except for 
OTHER (p < 0.01) and CHD (p < 0.05). 
Although the differences in average annual 
charges are quite large for PER1 and CAPDH, 
the variances were proportionally larger. This 
insignificance may be partially attributable to 
the small numbers of observations of diabetic 
patients on PERI and CAPDH. Charges were 
actually lower for diabetics using CAPDTR, a 
modality which is either an initial modality or 
an intermediate stage between use of CHD or 
PERI and CAPDH. Adding charges incurred 
during training to the charges for CAPDH 
yields total charges which are similar to those of 
CHD and PERI. 
In both the year of a transplant and after the 
transplant, charges were higher for diabetics 
than for nondiabetics. Charges were signifi- 
Table 3. Distribution of annual charges and percent of charges by 
source (1983 dollars) 





3976 3297 679 
(13.4%) (13.2%) (14.5%) 
13.945 13,887 
(47.0%) (55.696) (I.& 
11.750 7192 3958 
(39.6%) (31.2%) (84.3%) 
$29,67 1 $24,976 $4.695 
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Table 4. Annual charges adjusted for patient characteristics associ- 
ated with each treatment modality (1983 dollars) 
Modality Patient characteristics 
Center Center 
hemodialysis peritoneal dialysis Home CAPD 
(CHD) (PERU (CAPDH) 
CHD 27,463 29,30 1 27,169 
PERI 25,879 26,486 23,612 
CAPDH 30,891 31,287 29,435 
“Indicates that no differences between amounts are significant, 
p < 0.05, two-tailed test. bColumns are based on average patient 
characteristics. CR~~~ are based on use of each modality. 
cantly higher for cadaver transplants in the year 
of a transplant. In the year after a transplant the 
differences in charges were smaller than the dif- 
ferences in the year of the transplant, and very 
small for living-related transplants. Differences 
in transplantation charges between diabetics 
and nondiabetics are similar in magnitude to 
differences in dialysis charges, although no two 
values are exactly the same. 
Holding patient characteristics constant and 
adjusted for the selection of particular dialysis 
modalities reduced the difference in charges 
among modalities. These comparative annual 
charges for selected modalities and diabetics 
only are presented in Table 4. The interpretation 
of these values is that the charges in each 
column represent the estimated annual charges 
assuming that the average age, sex, race, time 
since onset of ESRD and proportion dying are 
the same. The only factor explaining the differ- 
ence between two columns is the use of the 
average patient characteristics of patients using 
a given modality. Similarly, the only factor 
explaining the difference between two rows is 
the use of one modality vs some other modality 
of treatment. For example, a patient currently 
using CHD (column 1) would be expected 
to incur charges of $27,463 when using CHD 
(row 1), but only $25,879 when using PER1 
(row 2). 
DISCUSSION 
The two questions addressed in this paper are: 
(1) are diabetic patients with ESRD more ex- 
pensive to treat than nondiabetic patients; and 
(2) are there cost differences among treatment 
modalities that could be used to help control 
costs. The answers, briefly, are yes and probably 
no, repectively. 
For most treatment modalities, annual 
charges were higher for diabetics than nondia- 
betics, but many differences were insignificant. 
Overall, charges for diabetics were $4695 more 
per year than charges for nondiabetics. Of these 
additional charges, the majority were for in- 
patient services and the remainder for physician 
services and medical supplies. As suggested 
above, this observation is partially attributable 
to Medicare’s reimbursement system. While 
there is no necessary reason for higher charges 
for hospitalization, physical services and sup- 
plies of diabetics to be associated with higher 
costs for dialysis treatments (the bulk of out- 
patient charges), there is no clear reason for 
costs to be nearly identical for diabetics and 
nondiabetics. It is expected, that the inpatient, 
physicial and supply charges reflect differences 
in the complexity and quantity of treatments for 
ESRD in diabetics which are not reflected in the 
charges for outpatient services because of the 
system of reimbursement. The actual difference 
in resources used to treat diabetics as compared 
to nondiabetics is probably underestimated by 
the difference in charges. 
For diabetic patients electing dialysis treat- 
ments for ESRD, the costs are very similar 
among modalities, adjusting for patient charac- 
teristics and selection. Table 4 suggests that 
there may be some potential for cost savings by 
encouraging diabetic patients on CHD or 
CAPD to use PERI, but the expected savings 
are statistically insignificant and could be out- 
weighed if there are costs or complications 
involved with changing modalities. While it 
appears that PER1 is the cheapest form of 
treatment, a result which might not be expected, 
we regretfully do not have any insights to 
explain this result. There may be individual 
diabetic patients whose characteristics more 
closely match those of patients using other 
modalities which, on average, are less expensive. 
However, having the average patient using each 
dialysis modality change modality to one which 
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is, on average, less expensive would not 
yield cost savings. This result is also influenced 
by the Medicare payment system which explic- 
itly sets equal payment rates for home and 
center dialysis. A measure of the real cost of 
resources consumed by patients on each modal- 
ity might yield different results. However, no 
such measure is available. Given the lack of 
significant differences in charges, decisions on 
dialysis modality selection should, and most 
likely already are, based on other considerations 
such as expected survival and quality-of-life. 
In both the year of a transplant and after the 
transplant, charges were higher for diabetics 
than for nondiabetics. However, this does not 
suggest that transplants are not a cost-effective 
modality of treatment for diabetics. While the 
charges are higher for transplants in diabetics, 
the cost saving realized by a successful trans- 
plant are also higher. For example, if a patient 
on CHD were to receive a transplant from a 
cadaver donor, the savings in each year follow- 
ing a successful transplant would by $17,774 
($23,47&5696) for the nondiabetic and $19,138 
($27,463%8325) for the diabetic. In both cases 
the additional charge for the transplant would 
be paid back in terms of future saving within 5 
years. The time to payback is nearly identical 
for diabetic and nondiabetic patients receiving 
transplants from either cadaver or living-related 
donors, even when probability of failure is 
included. The question of cost-effectiveness, or 
relative cost-effectiveness ultimately rests on the 
issue of expected survival after transplantation. 
The crude death rate in this sample and evidence 
from other studies suggests that survival is lower 
for diabetics than nondiabetics [18]. 
The next question which naturally arises is 
whether more diabetic patients should receive 
transplants. This analysis would suggest the 
answer is yes, but it is more difficult to evaluate 
for at least two reasons. First, suitable kidneys 
for transplantation are scarce and, therefore, 
transplant patients routinely receive extensive 
evaluations prior to becoming transplant candi- 
dates. Acceptance or rejection is frequently 
based on the outcome of coronary angiography, 
overall health status and age. A comparison of 
the relative health of diabetics vs patients with 
hypertension and other diseases is necessary to 
fully answer this question. 
And second, as a result of the screen- 
ing, patients accepted for transplantation are 
healthier and are less likely to die than dialysis 
patients. Therefore, the most cost-effective 
transplants may be those currently being per- 
formed, although this is not necessarily true in 
every case. When Khauli compared a group of 
diabetics who received transplants to a group of 
transplant candidates, for whom no acceptable 
kidney could be found, no significant difference 
in survival was seen in 24 months, although 
the trend towards better survival of those 
transplanted was beginning to emerge [ 191. 
Although these results present a more dr:- 
tailed view of ESRD charges for diabetics than 
has been previously available, three cautions in 
their use are necessary. First, the data did not 
take into consideration the many individual 
characteristics of the patient’s medical, social 
and emotional status. Some of these character- 
istics may be very important in terms of treat- 
ment selection and the ultimate success of a 
particular modality. Second, measures of im- 
provement of stabilization of retinopathy, neu- 
ropathy or quality-of-life were not available for 
this analysis. These too may affect the results 
presented. And third, total charges for patient 
care were used rather than the marginal costs of 
ESRD treatment alone. Available data do not 
permit the separation of charges associated with 
ESRD, diabetes and other conditions. It is 
expected that a measure of resource costs would 
yield a larger difference between the costs of 
ESRD treatment for diabetics and nondiabetics. 
It is also possible that certain modalities are 
truely less expensive than others for particul;ir 
patients, but that the use of medical services for 
other conditions and the nature of the reim- 
bursement system did not allow these advan- 
tages to be observed. Not having found these 
less expensive modalities means that potential 
opportunities for saving may be missed. 
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